Date: 2017-03-20
Type of information: Development agreement
Compound: antagonists of a novel target for a variety of metabolic indications
Company: Arix Bioscience (UK) the Lead Discovery Center (Germany) Max Planck Innovation (Germany) the University of Leeds (UK)
Therapeutic area: Cardiovascular diseases - Metabolic diseases
Type agreement:
Action mechanism:
Disease:
Details: On March 20, 2017, Arix Bioscience has signed an agreement with the Lead Discovery Center, Max Planck Innovation , and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations. Under the terms of the agreement, Arix Bioscience will fund and manage experimental work that builds on fundamental discoveries from the faculty of cardiovascular medicine and diabetes at the University of Leeds and the Lead Discovery Center, focusing on the development of antagonists of a novel target for a variety of metabolic indications. This collaboration originated from a strategic agreement signed between Arix Bioscience and the Lead Discovery Center in 2016, under which the Lead Discovery Centershares pipeline projects with Arix Bioscience. This is the first project to arise from this agreement.
Financial terms:
Latest news:
